Fredrik Henell
Vorstandsvorsitzender bei Axcentua Pharmaceuticals AB
Profil
Fredrik Henell is currently the Chief Executive Officer & Director at Synphora AB and Axcentua Pharmaceuticals AB.
He previously worked as the Senior Vice President-Business Development at ZymoGenetics, Inc. He holds a doctorate degree from Karolinska Institutet and an MBA from the University of Stockholm.
Aktive Positionen von Fredrik Henell
| Unternehmen | Position | Beginn |
|---|---|---|
Axcentua Pharmaceuticals AB
 Axcentua Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Axcentua Pharmaceuticals AB develops anti-cancer drugs for pancreatic cancer patients. It generates investigational new drugs for diseases with unmet medical need in Sweden. The firm offers AXP107-11, multi-targeted chemosensitizer and a small-molecule anti-cancer compound for the treatment of various solid tumors, such as non-small cell lung cancers. The company was founded in 2007 by Anders Berkenstam, Stefan Rehnmark and Michael-Robin Witt and is headquartered in Stockholm, Sweden. | Vorstandsvorsitzender | - |
Synphora AB
 Synphora AB Pharmaceuticals: MajorHealth Technology The Swedish company was founded in 2004 by Johan Stjernschantz and is currently led by CEO Fredrik Henell. | Vorstandsvorsitzender | - |
Ehemalige bekannte Positionen von Fredrik Henell
| Unternehmen | Position | Ende |
|---|---|---|
ZymoGenetics, Inc.
 ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | Corporate Officer/Principal | - |
Ausbildung von Fredrik Henell
| University of Stockholm | Masters Business Admin |
| Karolinska Institutet | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
ZymoGenetics, Inc.
ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | Health Technology |
Axcentua Pharmaceuticals AB
Axcentua Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Axcentua Pharmaceuticals AB develops anti-cancer drugs for pancreatic cancer patients. It generates investigational new drugs for diseases with unmet medical need in Sweden. The firm offers AXP107-11, multi-targeted chemosensitizer and a small-molecule anti-cancer compound for the treatment of various solid tumors, such as non-small cell lung cancers. The company was founded in 2007 by Anders Berkenstam, Stefan Rehnmark and Michael-Robin Witt and is headquartered in Stockholm, Sweden. | Health Technology |
Synphora AB
Synphora AB Pharmaceuticals: MajorHealth Technology The Swedish company was founded in 2004 by Johan Stjernschantz and is currently led by CEO Fredrik Henell. | Health Technology |
